Ironwood Pharmaceuticals (IRWD) : Bridger Management reduced its stake in Ironwood Pharmaceuticals by 33.68% during the most recent quarter end. The investment management company now holds a total of 3,924,333 shares of Ironwood Pharmaceuticals which is valued at $65,418,631 after selling 1,993,330 shares in Ironwood Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Ironwood Pharmaceuticals makes up approximately 4.73% of Bridger Management’s portfolio.
Other Hedge Funds, Including , Weiss Multi-strategy Advisers reduced its stake in IRWD by selling 2,415 shares or 2.45% in the most recent quarter. The Hedge Fund company now holds 96,000 shares of IRWD which is valued at $1,600,320. Ironwood Pharmaceuticals makes up approx 0.13% of Weiss Multi-strategy Advisers’s portfolio. Tfs Capital sold out all of its stake in IRWD during the most recent quarter. The investment firm sold 62,909 shares of IRWD which is valued $1,039,886.Blackrock Investment Management boosted its stake in IRWD in the latest quarter, The investment management firm added 4,591 additional shares and now holds a total of 486,291 shares of Ironwood Pharmaceuticals which is valued at $6,895,606. Ironwood Pharmaceuticals makes up approx 0.01% of Blackrock Investment Management’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in IRWD in the latest quarter, The investment management firm added 42,117 additional shares and now holds a total of 3,335,616 shares of Ironwood Pharmaceuticals which is valued at $47,299,035. Ironwood Pharmaceuticals makes up approx 0.01% of Blackrock Institutional Trust Company N.a.’s portfolio.
Ironwood Pharmaceuticals closed down -0.08 points or -0.49% at $16.11 with 13,34,857 shares getting traded on Monday. Post opening the session at $16.28, the shares hit an intraday low of $15.91 and an intraday high of $16.31 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Ironwood Pharmaceuticals reported $-0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.23. The company had revenue of $66.00 million for the quarter, compared to analysts expectations of $60.01 million. The company’s revenue was up 66.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.25 EPS.
Many Wall Street Analysts have commented on Ironwood Pharmaceuticals. Company shares were Reiterated by Mizuho on Nov 4, 2016 to “Buy”, Firm has raised the Price Target to $ 20 from a previous price target of $19 .Company shares were Reiterated by Wedbush on Oct 24, 2016 to “Neutral”, Firm has raised the Price Target to $ 13 from a previous price target of $10 .Shares were Reiterated by Mizuho on Oct 10, 2016 to “Buy” and Lowered the Price Target to $ 19 from a previous price target of $24 .
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.